Events & Presentations

View all events

Financial Reports and Filings

Date Filing Title Downloads
10/11/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
10/11/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
10/10/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
10/10/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
10/10/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
10/09/2024 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
09/23/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/23/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/23/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/16/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
View all filings

Latest News

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration Thumbnail

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

Oct 15, 2024 | Products

Read more
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer Thumbnail

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Oct 08, 2024 | Products

Read more
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics Thumbnail

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

Oct 03, 2024 | Products

Read more
View all news releases

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics